Scientific Presentations
2024
Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacy. These data were presented by Rom S. Leidner, M.D., during the Society for Immunotherapy of Cancer (SITC) Annual Meeting held 7-10 November in Houston, TX.
Dark Immunopeptidome of Head and Neck Squamous Cell Carcinoma in Serial Cell Lines from a Single Patient During Multimodality Treatment Time-Course. These data were presented during the Society for Immunotherapy of Cancer (SITC) Annual Meeting held 7-10 November in Houston, TX.
An Off-the-Shelf Multivalent Vaccine Containing Cancer’s Dark Matter, DPV-001, Combined with PD-1 +/- GITR in Head & Neck Cancer: Safety, Efficacy, and Immunodynamics from the Phase 1 GITRVax Trial. These data were presented by Rom S. Leidner, M.D., during the First-in-Human Phase I Clinical Trials Session 1 on April 8 (No. CT112, Poster Section 48, 1:30 to 5pm), at the American Association for Cancer Research Annual Meeting held 5-10 April in San Diego, CA.
Developing Combination Immunotherapy Trials with Vaccines that Contain Cancer’s Dark Matter. Invited talk in NCI Distinguished Lecturer Series, recording of virtual lecture, NCI, NIH, Bethesda, MD. January 11, 2024
2023
Peptidomics: Unraveling the Universe of Peptides Cancer Cells Display. Invited talk, European Society for Medical Oncology (ESMO) Immuno-Oncology Meeting, Geneva, Switzerland, December 7, 2023
Principles of Tumor Immunity. Invited talk, ESMO-SITC Primer, ESMO Immuno-Oncology Meeting, Geneva, Switzerland, December 6, 2023
Cancer Vaccines. International Union of Immunological Societies (IUIS) – SITC Cancer Immunotherapy Primer, Cape Town, South Africa, November 27-December 2, 2023
Strategies to Augment Combination Immunotherapy with Cancer Vaccines. CanSino Biologics, Pudong, China, November 15, 2023
Cancer Immunotherapy. Invited Talk, ImmuXell Biotech, Pudong, China, November 14, 2023
Developing Combination Immunotherapy that Includes Cancer Vaccines, Invited plenary session speaker, 4thZhangjiang Cell and Gene TherapyIndustry International Summit & 4th Symposium on Synthetic Immunology, Shanghai, China, November 11-12, 2023
Developing Combination Immunotherapy with Cancer Vaccines. Translational Immuno-Oncology Symposium, Guangzhou, China, November 10, 2023
Multi-parametric Assessment of the Immune Response to a Trio Immunotherapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Presentation at Society for Immunotherapy of Cancer (SITC), San Diego, CA, November 2-5, 2023
Characterizing Cancer’s Dark Matter, Short-lived Proteins, and Defective Ribosomal Products, Presented by Cancer and Contained in the DPV-001 Cancer Vaccine. Presentation at Society for Immunotherapy of Cancer (SITC), San Diego, CA, November 2-5, 2023
Peptidomics: Identifying Cancer’s Dark Matter and Canonical Targets - A possible Strategy for Universal Cancer Vaccines. Invited Talk, Siena Think Tank VII, Siena, Italy, October 5-7, 2023
Developing Combination Immunotherapy with Agents lacking Strong Single Agent Therapeutic Activity: Cancer Vaccines - a Case in Point, Invited presentation, Incyte HQ, Willmington, DE, September 18, 2023
Developing Combination Immunotherapy with Cancer Vaccines. Invited talk in Cancer Vaccines Session, Parker Institute for Cancer Immunotherapy Fall Retreat. Rosewood Miramar Beach, Montecito, CA, September 11-14, 2023
Applying Proteogenomics to Identify Cancer’s Non-Canonical Alternative Neoantigens and the Development of Immunotherapies Targeting Those Antigens and Other SLiPs Invited talk, Tumor Immunology Meets Oncology (TIMO), Halle, Germany, April 22, 2023
Trial in Progress: First-in-Human Immunotherapy-Trio for Advanced Head and Neck Squamous Cell Carcinoma Presentation at AACR, Orlando FL, April 19th 2023
Immune Interception of Pre-Malignancy Invited lecture, SITC Immunoprevention Virtual Summit, April 3, 2023
Applying Proteogenomics to Identify Cancer’s Non-Canonical Alternative Neoantigens and the Development of Immunotherapies Targeting Those Antigens IO360 Immuno-Oncology Conference, Brooklyn, NY, February 7 – 10, 2023
2022
Progress in Cellular Immunotherapy - It is not Just Mutations: A Vision into Combinations to Expect in 2023 and Beyond Invited lecture for Breast Cancer Transformation Forum, Breast Cancer Expert Committee, Chinese Society for Clinical Oncology (CSCO), Guangzhou, China, December 18, 2022
A Vision to Cure More Patients with Cancer by Better Identifying the Impact of Treatment and Modifying Therapy Appropriately Invited Lecture, Multi-omics Conference, Brisbane, Australia, December 11th – 13, 2022
Preliminary immunological monitoring of first-in-human immunotherapy-trio of multivalent autophagosome vaccine, anti-GITR and anti-PD-1 Presentation at Immunotherapy and Melanoma Bridge, Naples, Italy, November 30th – December 3rd, 2022
Development of a Vaccine to Intercept Oral Cancer Presentation at SITC, Boston, MA, November 10-12, 2022
Uncovering the Dark Immunopeptidome of Head and Neck Squamous Cell Carcinoma (HNSCC): Relevance for Universal Cancer Vaccines, Immunological Monitoring and TIL Therapy Presentation at SITC, Boston, MA, November 10-12, 2022
Cancer Vaccines: A Phoenix Rising from the Ashes Virtual lecture for opening of CanWell Biotech’s offices and R&D facility in Guangzhou, China, September 5, 2022
Complex Cancer Vaccines: An Approach to Induce Immunity Against Gastroesophageal Malignancies in 2022 Conference organized by Stand Up 2 Cancer (SU2C) / Torrey Coast Foundation GEMINI, Houston, Texas July 6-7, 2022
Preliminary Immunological Monitoring of First-in-Human Immunotherapy- Trio for Advanced Head and Neck Squamous Cell Carcinoma Presented at AACR, New Orleans, April 8-13, 2022
Triplet Immunotherapy for Head and Neck Cancer: Complex Vaccines, T cell Agonists, and Checkpoint Blockade Grand Rounds, Roswell Park Cancer Center, Buffalo, NY, March 18, 2022
2021
Immunogenic cell death and antigen release Invited lecture, Joint Society for Immunotherapy of Cancer – European Society of Medical Oncology Immuno-Oncology Primer (virtual) at ESMO I-O Conference, Geneva, Dec. 8, 2021
Evaluating the cancer surfaceome: A possible strategy to identify targets and monitor immunity. Invited lecture Melanoma Bridge Immunotherapy Conference (Hybrid virtual/in-person), Napoli, Italy Dec. 3, 2021
Development and Clinical Translation of Combination Immunotherapy Invited Opening Lecture, Frontiers in Cancer Science (FCS)/(virtual), Singapore, Singapore, Nov. 1-3, 2021
Translation: An Iterative and Team Process – Our Path to the Development of Triplet Cancer Immunotherapy First Giorgio Parmiani Keynote Lecture. XIX Network Italiano per la Biotherapia dei Tumori (NIBIT) annual meeting (hybrid virtual/in-person), Oct. 14, 2021
Cancer vaccines in the ICI Era Think Tank V (hybrid virtual/in-person), Siena, Italy, Oct 8, 2021
Shared Immunogenic Cancer Antigens in Humans and Combination Immunotherapy Clinical Trials that Exploit Those Antigens Immunotherapy of Cancer 8 / ITOC 8 (virtual), Munich, Germany, Oct 8, 2021
Cancer Immunotherapy: From High Dose IL-2, to Immunosurveillance, to Triplets: What Cures Patients of Cancer? Hypotheses We are Testing in Clinical Trials Invited (virtual global) Grand Rounds, Pathology, AstraZeneca, May 13, 2021
What’s Next for Cancer Immunotherapy? Invited lecture (virtual), Advances in Cancer Immunotherapy Program, Society for Immunotherapy of Cancer April 8, 2021
Triplet Immunotherapy for Head and Neck Cancer: Complex Vaccines, T cell Agonists, and Checkpoint Blockade Invited lecture (virtual). International Immuno-Oncology Symposium, Center for Translational Cancer Research, University of Western Ontario, London, Ontario, Canada. February 9, 2021
2020
Immunotherapy-Induced Anti-Cancer Responses Invited talk, Melanoma Bridge, Virtual Meeting, Napoli, Italy, December 4, 2020
Anti-Cancer Immune Responses to the Spectrum of “Cancer Antigens” Invited talk, Melanoma Bridge, Virtual Meeting, Napoli, Italy, December 3, 2020
Cancer vaccines yesterday, today, and tomorrow: Cinderella no more? Invited lecture (virtual), European Society of Medical Oncology (ESMO)/ Asia, Singapore, Singapore, November 22, 2020
Biomarkers, Preclinical Studies and the Development of Combination Immunotherapy for Metastatic Triple Negative Breast Cancer Invited lecture (virtual), China Center for Food and Drug International Exchange (CCFDIE), Beijing, China, October 16, 2020
Biomarkers, Preclinical Studies and the Development of Novel Immunotherapy for Head and Neck Cancer Chinese Society for Clinical Oncology (CSCO) Annual Meeting – Invited lecture (virtual), Xiamen, China, August 21, 2020
Characterizing the Spectrum of Anticancer Immune Responses: What is Important? Marseille Immunopole Conference, Marseille, France, February 6, 2020
2019
Immunotherapy-Induced anti-cancer responses to the spectrum of “Cancer Antigens” Immunotherapy Bridge Conference, Napoli, Italy, December 6, 2019
Lessons from Human Studies that are Informing the Design and Evaluation of a New Generation of Combination Immunotherapy Trials
Peking University Cancer Center, Beijing, China, October 16 2019
A Vaccine Strategy to Intercept Premalignant Oral Dysplasia Before it Becomes Cancer
4th New Horizons in Immunotherapy for Head and Neck Cancer, Newberg, Oregon, August 16, 2019
Future Concepts to Understand and Optimize Immunotherapy
Invited lecture, 65th Heidelberg Grand Rounds. Thorax Klinik, University of Heidelberg and Nationales Centrum Fur Tumorerkrankungen (NCT) Heidelberg. Heidelberg, Germany, July 16, 2019
Strategies to monitor and optimize cancer immunotherapy
Invited talk, Cancer and Microenvironment Interaction Conference, Taipei, Taiwan, July 6, 2019
Cancer Immunotherapy: Insights From the Past and a Vision for the Future
Invited talk, Translational Immunology Lecture, Else-Kroner-Foschungskolleg, Wurzburg, Germany, June 28, 2019
Cancer Immunotherapy in Evolution: Vaccination, Co-stimulation and Checkpoint Blockade
Invited talk, 4thInternational Conference on Immunotherapy, organized by ICVI. The Royal Society, London, UK, May 24-25, 2019
Strategies to Monitor and Optimize Costimulatory Effects of T Cell Agonists and Rescue Them From the Dustbin of Failed Single Agents
Invited talk, Tumor Immunology Meets Oncology (TIMO), Halle, Germany, April 26-27, 2019
Combination Immunotherapy with Vaccines Targeting a New Class of Cancer Antigens, Combined with T cell Agonists and Checkpoint Blockers
Invited talk, The Future of Health: Concept to Clinic, an Institute for Systems Biology Conference. Seattle, Washington. April 8, 2019
Latest Trends for Multi-Omics Integration in Combination Immunotherapy Trials
Invited talk in Definiens #INSPIRE SERIES2019, satellite session of AACR. Atlanta, Georgia, March 31, 2019
Possible use of Immunoprofiling to stratify or direct Combination Immunotherapy
Invited talk. Cambridge Healthcare Institute TriCon Conference on Cancer Immunotherapy. San Francisco, California, March 11-13, 2019
Evolving Concepts of Anticancer Immunity that May Help to #FinishCancer
Invited talk, A Deeper Dive – the Agonox Maui Meeting. The Fairmont Hotel, Maui, Hawaii, February 28, 2019
New Immune-Based Predictive Biomarkers and New Combinations of Immune Checkpoint Modulators
Invited talk. Marseille Immunopole, Marseille, France, January 16, 2019
2018
Agonist immunomodulatory monoclonal antibodies: Sequencing and Optimizing Combinations
Invited speaker ESMO I-O, Geneva, Switzerland, December 15, 2018
Cancer vaccines and strategy to develop combination immunotherapy with T cell agonists
Invited talk, Immunotherapy Bridge Conference, Napoli, Italy, December 6, 2018
Cancer Vaccines: Current and Perspective Challenges
Invited talk, Siena Consensus Conference. Siena, Italy October 25, 2018
Applying Advances in Genetics and Immunology to Develop Effective Immunotherapy for NSCLC Regardless of Tumor Mutational Burden
Invited talk, Korean Association for Lung Cancer MSIO Conference, Imperial Palace Seoul Hotel, Seoul, Korea, October 15, 2018
Personalizing Cancer Vaccines Is More Than Just Whole Exome Sequencing
Cambridge Health Institute, Boston, MA, August 30-31, 2018
Why is Overall Survival Not Better For Patients Receiving Checkpoint Blockers and What Can Be Done to Improve OS?
Invited lecture, Third New Horizons Head and Neck Cancer Symposium, Pittsburgh, PA, June 15-16, 2018
The Next Wave: Combination Immunotherapy with Vaccines targeting a New Class of Cancer Antigens, Combined with T cell Agonists and Checkpoint Blockers
Cambridge Health Institute Cancer Immunotherapy Meeting, Boston, MA, June 11-12, 2018
Insights into Cancer Immunosurveillance and a Vision for Improving Patient Outcomes with Combination Immunotherapy
Grand Rounds, Oncology Center of Excellence, US FDA, White Oak, MD, April 27, 2018
Future Directions: Combination Therapy and Moving to Early Stage Setting.
Immunotherapy Conference, Duke/National University of Singapore Academic Medical Centre, Singapore, Singapore, April 13, 2018
Developing NextGen Combination Immunotherapies that will Tackle the Worst Cancers.
Seminar, Division of Medical Oncology, SingHealth Duke/National University of Singapore Academic Medical Centre, Singapore, Singapore, April 11, 2018
Combo immunotherapies hold great promise for better outcomes and more cures.
Answer2Cancer, Portland Oregon, April 7, 2018
Sequencing Checkpoint Therapies
Keystone Symposia, “Cancer Immunotherapy: Combinations” Montreal, Quebec, Canada March 23-27, 2018
Investigating Crucial Factors that Determine the Success of Immune Checkpoint Combinations
Immune Checkpoint Inhibition Meeting, Boston, MA, March 20-21, 2018
Exploiting Insights in Immunology and Autophagy to Develop NextGen Combination Immunotherapies
Perlmutter Cancer Center, New York University, NY, NY, March 14, 2018
Immunoscore: A Brief History, Clinical Application and Strategies to Move IHC-Based Evaluations of Cancer to Stratify patients for Clinical Trials and Tailor Therapy.
Thoracic Oncology Centre Munich (TOM): “State of the Art 2018“ meeting, Munich, Germany, March 8 – 10, 2018
A Vision to Exploit NCI Prioritized Cancer Antigens and TCGA Data to Develop Combination Immunotherapy for Rare Cancers.
Keynote Address, International Workshop on Merkel Cell Carcinoma Research, Center for Cancer Research (CCR) Rare Tumor Initiative, National Cancer Institute (NCI) Shady Grove Campus, Rockville, Maryland, March 5, 2018
Exploiting Insights in Immunology and Autophagy to Develop NextGen Combination Immunotherapies that will Tackle the Worst Cancers.
University of Michigan Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, February 7, 2018
Development of Cancer Vaccine-Based Combination Immunotherapy Strategies to Conquer Cancer.
Invited Presentation, Noble Life Science Partners Scientific Advisory Board, Ft. Lauderdale, FL, January 29, 2018
2017
Multispectral Imaging, Cancer Vaccines, and A Strategy to Develop Combination Immunotherapy with T cell Agonists
Immunotherapy Bridge Meeting, Napoli, Italy, November 29, 2017
Update on immuno-oncology
IASLC and Taiwan Lung Cancer Society meeting, Taipei, Taiwan, October 28, 2017
Exploiting Autophagy to Induce Broad Anti-Cancer Immunity in Mice and Humans
Powering Precision Medicine. Boston, MA Oct 24, 2017
Agonistic antibodies in the era of antagonistic antibodies: monotherapy, combination and/or sequence
Sienna Consensus Conference, NIBIT and the Parker Foundation, Siena, Italy, October 7, 2017
Cancer Immunotherapy: A Vision for Improving Outcomes and Increasing Cures
Radium Hospitalet, University of Oslo, Oslo, Norway. Sept 1, 2017
Multispectral Imaging, Cancer Vaccines, and A Strategy to Develop Combination Immunotherapy
Karolinska Institute, IMTAC Immunology Summer Course, Sandhamn Island, Sweden August 28-30, 2017
How I-O Agents and Combination Therapies Change the Biomarkers: Information to Tailor Therapy
Next-Generation-Dx-Summit, Washington DC, August 18, 2017
Three Important Considerations for Developing Effective Imuno-Oncology Combinations: Immunity, Co-stimulation and Checkpoint Blockade
FDA-AACR: Oncology Dose Finding Workshop Part 3, Washington DC, July 20, 2017 https://www.fda.gov/Drugs/NewsEvents/ucm562746.htm
Progress in Immuno-oncology: Delivering Hope and Clinical Benefit to Cancer Patients
AACR-SITC Joint Congressional Briefing
Russell Senate Office Building, Capitol Hill, Washington DC, July 19, 2017
NextGen Biomarkers for Precision Immunotherapy and a strategy to Impersonalize Cancer
Institute for Systems Biology (ISB) Summer Course, Seatle, WA, June 21-22, 2017
Hurdles to Developing Combination Immunotherapy: Insights from Preclinical Studies of Agonists Plus Checkpoint Blockade and a NextGen Approach to Characterizing Immune Cells in Human Tumors
Celldex Scientific Advisory Board Meeting, ASCO, Chicago, IL, June 5, 2017
Exploiting Autophagy to Induce Broad Anti-Cancer Immunity in Mice and Humans: Holbrook Kohrt, MD, PhD, Memorial Lecture
ICVI Symposium, Royal Society, London, UK, May 13, 2017
Evaluation of the Anti-Cancer Immune Response in Tumors
Definiens Syposium, Amsterdam, The Netherlands, April 25-26, 2017
The Elements to Cure Cancer by Immunotherapy
Taiwan Society for Immunotherapy of Cancer, Taiwan, April 22, 2017
Possible Solutions to the Biggest Hurdles for Immuno-Oncology.
Venture Forum, World Vaccine Conference, Washington DC, April 12, 2017
Immuno-Oncology at a Tipping Point.
17th Annual World Vaccine Conference, Washington DC, April 12, 2017
Cancer Immunotherapy: A Vision for Improving Outcomes and Increasing Cures, Immuno-Oncology Combination Therapies:
FDA Policy Forum, Regulatory Science and Policy Tracks at the AACR Annual Meetings http://www.abstractsonline.com/pp8/#!/4292/session/127 Washington DC, April 4, 2017
Possible Solutions to the Biggest Hurdles for Immuno-Oncology
Sachs Venture Forum, New York, NY, March 28, 2017
Multispectral Imaging of the Tumor Environment: Focus on HPV- HNSCC
ITOC 4, Prague, CZ, March 19, 2017
Antigen Presentation Defects and Cytokine Storm - Mechanisms Cancer Exploits to Escape
International Immuno-Oncology Network, London, UK, February 28, 2017
2016
Basic Biology of Immunotherapy: Cancer Vaccine, Immune Checkpoint Therapy and More
Chinese University of Hong Kong, Hong Kong, China, November 19, 2016
Immunoscore/Immunoprofiling and Combination Immunotherapy Including Vaccines
World Life Science Conference, Beijing, China, Nov. 2, 2016
A Perspective on the Future of Immuno-Oncology Research
3rd Immuno-Oncology Academy, Taipei, Taiwan, Oct 29, 2016
Immuno-Oncology at a Tipping Point
Loyola University: Cardinal Bernardin Cancer Center Retreat
Chicago, IL - July 29, 2016
Impersonalization of Cancer: Development of a Universal Cancer Vaccine
University of Washington: MITR Conference
Seattle, WA, July 18, 2016
Impersonalization of Cancer: Development of a Universal Cancer Vaccine
Agonox Maui Meeting
Maui, HI - June 10, 2016
UbiVac
Sachs Immuno-Oncology Investor Forum
Chicago, IL - June 3, 2016
Recent Advances for the Immunotherapy of Advanced Cancer
Taiwan Joint Cancer Conference: Molecular Genetics Section
Taipei, Taiwan - May 14, 2016
Immuno-Oncology at a Tipping Point
Bayer
Berlin, Germany - May 2, 2016
A Universal Cancer Vaccine Alternative to Personalized Cancer Vaccine Strategies
Tumor Immunology Meets Oncology (TIMO)
Halle, Germany - April 28, 2016
Increased IgG Antibody Responses to Neoepitope and Native Peptides Containing High Affinity Domains for MHCI
AACR, Poster presented by Tyler W. Hulett
New Orleans, LA - April 16-20, 2016
Timing Of PD-1 Blockade Is Critical To Successful Synergy With OX40 Costimulation In Preclinical Mammary Tumor Models
AACR, Oral presentation, David Messenheimer
New Orleans, LA - April 16-20, 2016
Immunotherapy at a Tipping Point
Molecular Med TriCon
San Francisco, CA - March 10-11, 2016
Cancer Vaccines and Combination Immunotherapy. At Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer
The National Academies of Sciences, Engineering, and Medicine: Institute of Medicine
Washington, DC 20001 - February 29, 2016
The Promise of Immunotherpy in Curing Patients with Cancer
Annual meeting of the Oncology Association of Naturopathic Physicians
Phoenix, AZ - February 28, 2016
The Next Phase for Cancer Immunotherapy
Janssen Research Center
Leiden, Netherlands - February 8, 2016
Clinical Updates for Novel Targets and Pathways: Application of Technologies and What They Tell Us?
PEP Talk
San Diego - January 18, 2016
